Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells.
We evaluated the effect of haloperidol (HP) and its metabolites on [(3)H](+)-pentazocine binding to sigma(1) receptors in SH-SY5Y human neuroblastoma cells and guinea pig brain P(1), P(2) and P(3) subcellular fractions. Three days after a single i.p. injection in guinea pigs of HP (but not of other sigma(1) antagonists or (-)-sulpiride), [(3)H](+)-pentazocine binding to brain membranes was markedly decreased. Recovery of sigma(1) receptor density to steady state after HP-induced inactivation required more than 30 days. HP-metabolite II (reduced HP, 4-(4-chlorophenyl)-alpha-(4-fluorophenyl)-4-hydroxy-1-piperidinebutanol), but not HP-metabolite I (4-(4-chlorophenyl)-4-hydroxypiperidine), irreversibly blocked sigma(1) receptors in guinea pig brain homogenate and P(2) fraction in vitro. We found similar results in SH-SY5Y cells, which suggests that this process may also take place in humans. HP irreversibly inactivated sigma(1) receptors when it was incubated with brain homogenate and SH-SY5Y cells, but not when incubated with P(2) fraction membranes, which suggests that HP is metabolized to inactivate sigma(1) receptors. Menadione, an inhibitor of the ketone reductase activity that leads to the production of HP-metabolite II, completely prevented HP-induced inactivation of sigma(1) receptors in brain homogenates. These results suggest that HP may irreversibly inactivate sigma(1) receptors in guinea pig and human cells, probably after metabolism to reduced HP.
Cobos
Enrique J
EJ
Department of Pharmacology and Institute of Neuroscience, Faculty of Medicine, University of Granada, Granada, Spain.
del Pozo
Esperanza
E
Baeyens
José M
JM
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects* / Q000502:physiology; D001921:Brain / Q000187:drug effects* / Q000378:metabolism; D045744:Cell Line, Tumor; D018492:Dopamine Antagonists / Q000494:pharmacology; D006168:Guinea Pigs; D006220:Haloperidol / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008297:Male; D015394:Molecular Structure; D009292:Narcotic Antagonists / Q000378:metabolism; D009474:Neurons / Q000187:drug effects* / Q000378:metabolism; D010423:Pentazocine / Q000378:metabolism; D011869:Radioligand Assay; D011940:Receptor Aggregation / Q000187:drug effects / Q000502:physiology; D017480:Receptors, sigma / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013347:Subcellular Fractions; D000097605:Sigma-1 Receptor
D018492:Dopamine Antagonists; D006220:Haloperidol; D009292:Narcotic Antagonists; D010423:Pentazocine; D017480:Receptors, sigma; D000097605:Sigma-1 Receptor